Drug recall · November 21, 2018
AMITIZA recall
Why: Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Pharma Americas, LLC, Rockville MD 20850 and Takeda Pharmaceuticals America, Inc. Deerfield, IL 60015. Active Ingredient made in Japan, encapsulated in the United States. NDC 64764-080-60
- Lots / codes
Lot # 3098628-61, exp. date 02/28/2021
- Quantity
- 69,075 60-count bottles (4,144,500 capsules)
- Company
- Takeda Development Center Americas, Inc., Deerfield, IL
- Distribution
- Product was distributed to 32 distributors throughout the United States.
- Initiated
- November 6, 2018 · Voluntary: Firm initiated
- Classified
- November 28, 2018
- Reported
- November 21, 2018
- Ended
- June 20, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amitiza
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.